Nitric Oxide for Stroke

Phase-Based Progress Estimates
Nitric Oxide - Drug
All Sexes
What conditions do you have?

Study Summary

This trial is measuring the cerebral blood flow response to inhaled nitric oxide in acute ischemic stroke patients and healthy subjects.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Stroke

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: Conclusion of the 35 minute protocol

Conclusion of the 35 minute protocol
Change in blood flow velocity as measured by TCD during iNO administration
Change in cerebral blood flow during the administration of iNO
Change in mean arterial blood pressure (MAP) during iNO administration
Duration of residual effect after cessation of iNO (time to return to baseline)
Time to maximum CBF effect after the introduction of iNO

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Other trials for Stroke

Trial Design

2 Treatment Groups

Acute Ischemic Stroke
1 of 2
Healthy Controls
1 of 2
Experimental Treatment

40 Total Participants · 2 Treatment Groups

Primary Treatment: Nitric Oxide · No Placebo Group · Phase 2

Acute Ischemic Stroke
Experimental Group · 1 Intervention: Nitric Oxide · Intervention Types: Drug
Healthy Controls
Experimental Group · 1 Intervention: Nitric Oxide · Intervention Types: Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
Nitric Oxide
FDA approved

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: conclusion of the 35 minute protocol

Who is running the clinical trial?

Steven MesseLead Sponsor
MallinckrodtIndustry Sponsor
199 Previous Clinical Trials
16,558 Total Patients Enrolled
Steven R Messe, M.D.Principal InvestigatorUniversity of Pennsylvania

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 20th, 2021

Last Reviewed: October 26th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.